In the Phase 3 trial, the investigational 2 mg dose of Ozempic® (semaglutide) injection had a better blood glucose reduction compared to Ozempic® 1 mg in adults with type 2 diabetes – QNT Press Release

[ad_1]

Plainsboro, New Jersey, June 26, 2021/PRNewswire/–Novo Nordisk’s data released today shows that an investigational 2 mg dose of Ozempic^® Compared with Ozempic, (semaglutide) injection can significantly reduce blood sugar (A1C)^® 1 mg.¹ These data are the results of the SUSTAIN FORTE test, which is a stage 3b, To compare the efficacy and safety of semaglutide 2 mg once a week with Ozempic for 40 weeks^® In 961 adult patients with type 2 diabetes who needed to further lower blood sugar, 1 mg was used as an additive to metformin, with or without sulfonylureas. The result is 81^Yingshi American Diabetes Association (ADA) Annual Scientific Meeting^1,2 The main results are being published The Lancet Diabetes and Endocrinology.

The trial reached its primary endpoint, that is, people who received 2 mg of semaglutide once a week and had an average baseline A1C increase of 8.9% demonstrated that A1C decreased by 2.2%, which is statistically significant and superior, while Ozempic decreased by 1.9%^® After 40 weeks, I took 1 mg as expected.^{1 *}

A further post-event subgroup analysis presented at the conference showed that 2 mg semaglutide showed greater blood glucose reduction at 40 weeks compared to Ozempic^® 1 mg, across the baseline A1C subgroup (Table 1).²

“Some people with type 2 diabetes need extra support to reach their blood sugar goals,” said the doctor. Juan Pablo Frias, Medical Director of the National Academy of Sciences, angel And the lead researcher of SUSTAIN FORTE. “The decrease in blood glucose observed with semaglutide 2 mg suggests that higher doses of Ozempic^® May provide individuals with the opportunity to further improve diabetes control, and its tolerance is comparable to Ozempic^® 1 mg. “

Starting from an average baseline weight of 99.3 kg, semaglutide 2 mg showed a statistically significant weight loss of 6.9 kg compared to Ozempic’s 6.0 kg^® 1 mg.^† According to the treatment policy estimand, people who received semaglutide 2 mg lost 6.4 kg, while Ozempic lost 5.6 kg.^® 1 mg. A further post-hoc analysis presented in the baseline BMI subgroup showed that semaglutide 2 mg had a non-significant reduction in body weight compared to the 1 mg dose (Table 1).²

In the main analysis, the incidence of adverse events (AE) at the two doses was similar, including gastrointestinal events (nausea, diarrhea, and vomiting). Gastrointestinal events are the most common AEs associated with GLP-1 RA, including Ozempic^®.

“Ozempic^® It has helped millions of people with type 2 diabetes reduce blood sugar around the world. Although there is no indication for weight loss, it has been proven that some patients lose weight. It also helps reduce the risk of major cardiovascular events in adults with type 2 diabetes and cardiovascular disease,” Martin Lange, Executive Vice President of Novo Nordisk. “For nearly a century, our mission has been to promote diabetes treatment and innovative changes to improve the lives of diabetic patients. These data show that with a higher dose of 2 mg of semaglutide, we can help more people with diabetes. Of adults with type 2 diabetes who have poor blood sugar control have lower A1C.”

The full story on Benzinga.com

[ad_2]

Source link